EP3805233
(R) og (S) handhverfur N-(5-(3-hýdroxýpýrrólídín-1-ýl)-2-morfólínóoxasóló[4,5-b]pýridín-6-ýl)-2-(2-metýlpýridín-4-yl)oxasól-karboxamíðs sem irak4 hemlar til meðferðar á krabbameini
:
EP einkaleyfi í gildi á Íslandi:
12.1.2015:
6.3.2024:
20211096.1
:
8.4.2024:
15.5.2024
:
11.1.2035:
11.1.2026:
31.1.2026
:
(R) AND (S) ENANTIOMERS OF N-(5-(3-HYDROXYPYRROLIDIN-1-YL)-2-MORPHOLINOOXAZOLO[4,5-B]PYRIDIN-6-YL)-2-(2-METHYLPYRIDIN-4-YL)OXAZOLE-CARBOXAMIDE AS IRAK4 INHIBITORS FOR THE TREATMENT OF CANCER
12.1.2015
6.3.2024
8.4.2024
15.5.2024
11.1.2026
:
Aurigene Oncology Limited:
39-40 KIADB Industrial Area Electronic City Phase II Hosur Road, Bangalore 560100, IN
:
GUMMADI, Venkateshwar, Rao:
560100 Bangalore, IN
:
SAMAJDAR, Susanta:
560078 Bangalore, IN
:
Árnason Faktor ehf.:
Guðríðarstíg 2-4, 113, Reykjavík,
:
158CH2014:
13.1.2014:
IN
:
3000CH2014:
20.6.2014:
IN
:
C07D 498/04, C07D 513/04, C07D 519/00, A61K 31/437, A61P 1/02, A61P 3/00, A61P 5/00, A61P 7/00, A61P 9/00, A61P 11/00, A61P 13/10, A61P 15/00, A61P 17/00, A61P 19/00, A61P 21/00, A61P 25/00, A61P 27/02, A61P 29/00, A61P 31/00, A61P 35/00, A61P 37/02
: 11
: 21.2.2025
: 11.1.2026
: Árnason Faktor ehf.